Exeantide in Type 2 Diabetes on Insulin
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | April 2008 |
| End Date: | May 2013 |
| Contact: | Cathy Gamel |
| Email: | cgamel@kaleidahealth.org |
| Phone: | 716-887-4523 |
The Effect of Exenatide on Insulin Requirement, Weight and Inflammation in Obese Type 2 Diabetic Subjects on Insulin
Exenatide has been shown to result in better glycemic control in type II diabetes patients.
Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to
decreased inflammation by virtue of better glycemic control and weight loss.
The purpose of this study is to determine if the addition of Exenatide to diabetic patients
will reduce the requirements of insulin particularly the short acting insulin. Exenatide
may also lead to decreased inflammation by virtue of better glycemic control and weight
loss, or an independent effect.
Inclusion Criteria:
- Males or females 20-75 years of age inclusive.
- Type 2 diabetes
- On insulin therapy
- HbA1c ≥7.5% and ≤ 9%
- BMI ≥ 30 kg/m2
- Subjects on statins, ACE inhibitors, metformin, thiazolidinediones and antioxidants
will be allowed as long as they are on stable doses of these compounds and the dosage
in not changed during the study.
Exclusion Criteria:
- Coronary event or procedure (myocardial infarction, unstable angina, coronary artery
bypass, surgery or coronary angioplasty) in the previous four weeks
- Pregnancy
- Hepatic disease (abnormal LFT's)
- Use of DPP4 inhibitors.
- Renal impairment (serum creatinine > 1.5)
- Participation in any other concurrent clinical trial
- Any other life-threatening, non-cardiac disease
- Uncontrolled hypertension (BP > 160/100 mm of Hg)
- Congestive Heart Failure.
- Use of an investigational agent or therapeutic regimen within 30 days of study
We found this trial at
1
site
Click here to add this to my saved trials
